Loading
Life sciences · Journal article
Open Research · August 26, 2026
Well-designed and adequately powered for the question it asks.
This standardized validation study demonstrates that mNGS achieves high analytical performance (100% concordance, LoD 10.0–269.1 copies/mL, no cross-reactivity) and superior clinical sensitivity (78.6% vs. 45.2%, p <.001) and accuracy (79.8% vs. 53.7%, p <.001) compared to conventional microbial culture in a large retrospective cohort. In a prospective cohort of 142 patients, mNGS informed antimicrobial decisions in 84% of infected cases (101/120), positioning it as a sensitive adjunct to conventional testing within a standardized framework.
Multi-phase analytical validation study with retrospective cohort comparison and prospective cohort assessment. Patients with suspected infection from clinical specimens; retrospective cohort n=499, prospective cohort n=142. Analytical validation performed on reference pathogen panel and simulated data.. Intervention: Metagenomic next-generation sequencing (mNGS) for pathogen identification from clinical specimens. Compared with: Conventional microbial culture and conventional microbiological testing (CMT). Not stated.
mNGS achieved 100% qualitative concordance across intra-run and inter-batch testing Limit of detection ranged from 10.0 to 269.1 copies/mL No cross-reactivity observed between closely related species
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
mNGS demonstrates markedly superior sensitivity and accuracy to conventional culture and identifies pathogens 4.8-fold faster, supporting its use as a sensitive diagnostic adjunct. Prospective data showing treatment impact in 84% of infected patients (101/120) indicates potential clinical utility, though the study positions mNGS as complementary rather than replacement therapy within a standardized validation and clinical adjudication framework.
Rigorous multi-phase validation study with analytical benchmarking, large retrospective cohort comparison, and prospective clinical impact assessment, demonstrating superior sensitivity and turnaround time versus culture; not practice-changing alone because it remains positioned as adjunct to conventional testing.
As stated by the source record.
Quoted from the source exactly as published.
mNGS demonstrates markedly superior sensitivity and accuracy to conventional culture and identifies pathogens 4.8-fold faster, supporting its use as a sensitive diagnostic adjunct. Prospective data showing treatment impact in 84% of infected patients (101/120) indicates potential clinical utility, though the study positions mNGS as complementary rather than replacement therapy within a standardized validation and clinical adjudication framework.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Metagenomic next‐generation sequencing (mNGS) enables unbiased identification of pathogens directly from clinical specimens. Despite its growing application in the diagnosis of infectious diseases, comprehensive validation of mNGS performance remains limited. This study systematically evaluated the analytical and clinical performance of mNGS through a standardized validation workflow, including analytical evaluation using a reference panel of 12 representative pathogens, in silico simulations involving 108 pathogens, evaluation of diagnostic performance in a retrospective cohort of 499 patients, and assessment of clinical impact in a prospective cohort of 142 patients. Our analyses revealed that mNGS achieved 100% qualitative concordance across both intra‐run and inter‐batch testing. The limit of detection (LoD) ranged from 10.0 to 269.1 copies/mL. No cross‐reactivity was observed between closely related species. Moreover, strong linearity supported its robustness and semiquantitative capability. In silico simulations further confirmed its high performance across a broader range of microorganisms. For the culture‐based comparison, mNGS demonstrated a markedly shorter laboratory turnaround time (28.6 h vs. 136.6 h, p <.001) and a higher positive detection rate (82.7% vs. 47.1%, p <.001) than microbial culture. Using composite clinical diagnosis as the reference standard, mNGS exhibited superior detection sensitivity (78.6% vs. 45.2%, p <.001) and overall accuracy (79.8% vs. 53.7%, p <.001) compared to conventional mictobiological testing (CMT). In the prospective cohort, mNGS contributed to antimicrobial treatment decisions in 101 of 120 infected patients. These findings demonstrate that mNGS may serve as a sensitive adjunct to CMT, particularly when interpreted within a standardized quality‐control and clinical adjudication framework.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.